Want to create an interactive transcript for this episode?
Podcast: PeerView Clinical Pharmacology CME/CNE/CPE Video
Episode: Luke Maese, DO, Rachel Rau, MD - Building a Foundation for Enhanced Outcomes in Pediatric ALL: Guidance on the Asparaginase Component of Modern Therapy
Description: Go online to PeerView.com/TAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibodies, tyrosine kinase inhibitors, cellular therapy, and modern asparaginases, such as pegylated Escherichia coli and Erwinia chrysanthemi compounds have vastly improved treatment plans for pediatric and adolescent and young adult (AYA) populations with acute lymphoblastic leukemia (ALL). The approval of newer Erwinia formulations has expanded the therapeutic foundation on which clinicians can build effective strategies to address challenges such as asparaginase discontinuation due to hypersensitivity or silent inactivation. This "Clinical Consults" activity focuses on clinical decision-making related...